Aethlon gets $6.8M DARPA contract; Abbott begins enrolling U.S. patients in EXCEL study;

> Aethlon Medical ($AEMD) has been awarded a $6.8 million contract from DARPA to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers. Aethlon release

> Abbott ($ABT) has begun enrolling U.S. patients in the EXCEL trial to assess the safety and efficacy of the XIENCE PRIME/XIENCE V everolimus-eluting coronary stent systems versus coronary artery bypass grafting or surgery in select patients with unprotected left main coronary artery disease. Abbott release

> Precision Engineered Products has purchased Boston Endo-Surgical Technologies, a manufacturer of spinal and orthopedic surgical instruments. The newly acquired company will be integrated into PEP's Lacey business unit, based in Bridgeport, CT. PEP release

> Bryan McMillan has been promoted to president of Orthofix International's ($OFIX) Spine Global Business unit. Orthofix release

> Cynosure ($CYNO) has acquired worldwide exclusive rights to distribute the PinPointe FootLaser from NuvoLase. Cynosure release

> Boston Scientific ($BSX) has started enrollment in a study to evaluate the safety and effectiveness of its OMEGA platinum chromium bare-metal coronary stent system in treating patients with a single coronary artery lesion. Boston Scientific release

And Finally... A family that owns land near a plant operated by Baxter International in Puerto Rico is suing the company for $50 million, alleging their property was contaminated with radioactive cobalt and other potentially hazardous materials. News

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.